← Every company
Madrigal Pharmaceuticals Inc Insider Trading
Every director, officer and 10% holder of Madrigal Pharmaceuticals Inc has to report each trade in its stock within two business days of making it. This is those filings.
MDGL on carbonthat →Insiders filing
3
39 reported lines
Open-market buys
0
Open-market sales
35
$7.9M
Net
$7.9M
sold more
Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| William John SiboldPresident and CEO2026-09-1160 shat $533.09 | Sale10b5-1 plan | $32K |
| William John SiboldPresident and CEO2026-09-11106 shat $534.06 | Sale10b5-1 plan | $56.6K |
| William John SiboldPresident and CEO2026-09-11218 shat $535.94 | Sale10b5-1 plan | $116.8K |
| William John SiboldPresident and CEO2026-09-11160 shat $537.62 | Sale10b5-1 plan | $86K |
| William John SiboldPresident and CEO2026-09-11687 shat $540.59 | Sale10b5-1 plan | $371.4K |
| William John SiboldPresident and CEO2026-09-11368 shat $541.64 | Sale10b5-1 plan | $199.3K |
| William John SiboldPresident and CEO2026-09-111.2K shat $542.60 | Sale10b5-1 plan | $652.2K |
| William John SiboldPresident and CEO2026-09-111.5K shat $544.02 | Sale10b5-1 plan | $837.3K |
| William John SiboldPresident and CEO2026-09-11761 shat $544.83 | Sale10b5-1 plan | $414.6K |
| William John SiboldPresident and CEO2026-09-11120 shat $546.38 | Sale10b5-1 plan | $65.6K |
| William John SiboldPresident and CEO2026-09-09131 shat $527.88 | Sale10b5-1 plan | $69.2K |
| William John SiboldPresident and CEO2026-09-09347 shat $529.27 | Sale10b5-1 plan | $183.7K |
| William John SiboldPresident and CEO2026-09-09522 shat $530.23 | Sale10b5-1 plan | $276.8K |
| William John SiboldPresident and CEO2026-09-09368 shat $531.99 | Sale10b5-1 plan | $195.8K |
| William John SiboldPresident and CEO2026-09-09512 shat $533.09 | Sale10b5-1 plan | $272.9K |
| William John SiboldPresident and CEO2026-09-09396 shat $534.20 | Sale10b5-1 plan | $211.5K |
| William John SiboldPresident and CEO2026-09-09644 shat $535.27 | Sale10b5-1 plan | $344.7K |
| William John SiboldPresident and CEO2026-09-091K shat $536.11 | Sale10b5-1 plan | $557.6K |
| William John SiboldPresident and CEO2026-09-09640 shat $537.17 | Sale10b5-1 plan | $343.8K |
| William John SiboldPresident and CEO2026-09-09520 shat $538.30 | Sale10b5-1 plan | $279.9K |
| William John SiboldPresident and CEO2026-09-09215 shat $539.03 | Sale10b5-1 plan | $115.9K |
| William John SiboldPresident and CEO2026-09-09505 shat $540.19 | Sale10b5-1 plan | $272.8K |
| William John SiboldPresident and CEO2026-09-09362 shat $541.65 | Sale10b5-1 plan | $196.1K |
| William John SiboldPresident and CEO2026-09-09160 shat $542.55 | Sale10b5-1 plan | $86.8K |
| Shannon T KelleyGeneral Counsel2026-08-17664 shat $514.97 | Sale | $341.9K |
| William John SiboldPresident and CEO2026-07-20140 shat $542.75 | Sale | $76K |
| William John SiboldPresident and CEO2026-07-20110 shat $543.79 | Sale | $59.8K |
| William John SiboldPresident and CEO2026-07-20545 shat $544.71 | Sale | $296.9K |
| William John SiboldPresident and CEO2026-07-20275 shat $545.71 | Sale | $150.1K |
| William John SiboldPresident and CEO2026-07-20269 shat $547.08 | Sale | $147.2K |
| William John SiboldPresident and CEO2026-07-20680 shat $547.70 | Sale | $372.4K |
| William John SiboldPresident and CEO2026-07-2047 shat $548.87 | Sale | $25.8K |
| William John SiboldPresident and CEO2026-07-20153 shat $550.01 | Sale | $84.2K |
| William John SiboldPresident and CEO2026-07-201 shat $550.72 | Sale | $550.7 |
| William John SiboldPresident and CEO2026-07-20280 shat $555.05 | Sale | $155.4K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on MDGL
Company overviewEverything on MDGL in one place, with the price.SEC filingsWhat MDGL's 8-Ks say happened: results, departures, auditor changes.Planned salesSales MDGL insiders have filed notice of.Who owns itEvery manager reporting a position in MDGL.Funds holding itWhich funds and ETFs hold MDGL, and how big a bet.LobbyingWhat MDGL spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on MDGL's account, and who they worked for.Federal contractsWhat federal agencies pay MDGL.PatentsWhat MDGL is filing at the patent office.
Follow Madrigal Pharmaceuticals Inc (MDGL) by email
New trades in Madrigal Pharmaceuticals Inc (MDGL) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.